FDA
-
-
-
-
-
-
-
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
-
-
-
-
-
-
-
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
-
-
-
-
-
-
-
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
-
-
-
-
-
-
-
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
-
-
-
-
-
-
-
Evolus (EOLS) Announces Acceptance of Submission in Australia
-
-
-
-
-
-
-
Evolus Joins Nasdaq Biotechnology Index
-
-
-
-
-
-
-
Evolus Announces Participation in September Investment Conferences
-
251,370 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All